Atorvastatin rescues pulmonary artery hypertension via inhibiting the AKT/ERK-dependent PDGF-BB/HIF-1α axis
| Autor: | Jianfei Chen, Kun Yang, Dehui Qian, Li Zhang, Mingbao Song, Yunfeng Shou, Linqiong Liu, Hanru Zhao |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
MAPK/ERK pathway
biology business.industry Atorvastatin General Medicine Hypoxia (medical) Pharmacology Downregulation and upregulation Apoptosis medicine.artery Pulmonary artery biology.protein Medicine medicine.symptom business Protein kinase B Platelet-derived growth factor receptor medicine.drug |
| Zdroj: | Panminerva medica. |
| ISSN: | 1827-1898 |
| Popis: | Background To explore the role of Atorvastatin in rescuing pulmonary artery hypertension (PAH) via inhibiting the AKT/ERK-dependent PDGF-BB/HIF-1α axis. Methods PAH model in rats was established by MCT induction, followed by Atorvastatin intervention. Pulmonary hemodynamic measurement and pulmonary morphological evaluation in rats were conducted. Human pulmonary artery smooth muscle cells (hPASMCs) were subjected to hypoxic exposure or PDGF-BB treatment, followed by Atorvastatin induction. Relative levels of HIF-1α, p-ERK and p-Akt were detected. Viability and apoptosis were respectively determined by cell counting kit-8 (CCK-8) assay and flow cytometry. Results Atorvastatin protected PAH-induced increases in RVSP and Fulton's index in rats. Meanwhile, it inhibited vascular remodeling following PAH by downregulating HIF-1α and PDGF-BB. Hypoxia or PDGF-BB treatment in hPASMCs resulted in upregulation of p-ERK and p-Akt, and viability increase, which were partially abolished by Atorvastatin intervention. In addition, Atorvastatin triggered apoptosis in hypoxia or PDGF-BB-induced hPASMCs. Conclusions Atorvastatin inhibits the activation of HIF-1α and proliferative ability, and triggers apoptosis in hPASMCs exposed to hypoxia or PDGF-BB treatment through inactivating the AKT/ERK pathway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|